Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...
Tukysa, combined with Herceptin and Perjeta, extends progression-free survival in HER2+ metastatic breast cancer, showing ...
AstraZeneca and Daiichi Sankyo’s Enhertu's breakthrough therapy designation as a post-neoadjuvant treatment option for ...
The 5 most-read breast cancer articles on AJMC.com this year included FDA approvals, emerging therapies for metastatic breast ...
The Susan G. Komen Breast Care Helpline provides information about breast health, breast cancer, local and national resources and information about clinical trials. To reach the free hotline, call ...
New NATALEE 5-year sub-analysis data reinforce sustained reduction in distant disease-free survival in broadest population of EBC patients13 ...
In a Phase 1 trial, women responded well to the novel vaccine. More research is needed to determine whether it can stop the ...
The 2025 San Antonio Breast Cancer Symposium brought plenty of data and bold new ideas to the thousands of clinicians, ...
Zacks Investment Research on MSN
AZN, Daiichi's Enhertu gets FDA nod for first-line breast cancer (revised)
AstraZeneca PLC AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody ...
Sacituzumab does not improve outcomes vs chemotherapy when used as the first treatment after endocrine therapy failure in HR+/HER2- advanced breast cancer, the ASCENT-07 trial finds.
MedPage Today on MSN
Overcoming CDK4/6 Inhibitor Resistance in HR-Positive/HER2-Negative Breast Cancer
In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...
Sacituzumab govitecan failed to extend PFS in patients with hormone receptor-positive, HER2-negative breast cancer following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback